2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.58K
Market Cap
€3.52M
Enterprise Value€39.03
Total Cash (Recent Filing)€7.63M
Total Debt (Recent Filing)€8.91M
Price to Earnings (P/E)―
Beta-82.94
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding1,711,808,500
10 Day Avg. Volume2,581
30 Day Avg. Volume2,581
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted PDT PlatformSpectraCure’s integrated photodynamic therapy platform is designed to deliver targeted, minimally invasive cancer treatment with real-time feedback. That combination may support clinical differentiation and a focused route to adoption if the technology demonstrates value in its initial prostate-cancer application.
Recurring Revenue ModelThe model combines upfront system sales with procedure-related consumables, creating a potential recurring revenue component as installed clinics perform treatments. If clinical adoption develops, consumable usage could improve revenue durability beyond one-time equipment purchases.
Low LeverageLow debt relative to equity limits direct balance-sheet pressure from borrowing and reduces exposure to interest and refinancing burdens. This provides some financial flexibility while SpectraCure develops its platform, although it does not offset the company’s ongoing operating losses.
Bears Say
No Revenue And Large LossesThe absence of reported revenue alongside very large net and operating losses indicates that the business has not yet established commercial traction. Continued investment without demonstrated sales or operating leverage leaves profitability dependent on future clinical adoption and successful commercialization.
Persistent Cash BurnSustained negative operating and free cash flow means current activities consume cash rather than fund themselves. This can require reliance on external funding or existing reserves to maintain development and operations, increasing financial vulnerability until cash generation improves.
Shrinking Equity BaseThe substantial reduction in equity shows that persistent losses are consuming the company’s capital base, while deeply negative return on equity confirms weak shareholder economics. Continued erosion can reduce financial resilience and raise the likelihood of future funding or dilution pressure.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was <€0.01 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €3.52M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 64 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Aug 21, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 1,711,808,500 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
BrainCool AB
―
ScandiDos AB
―